Published in Cancer on April 01, 2010
DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer | NCT02079363
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics (2011) 1.33
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer (2011) 1.30
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
DNA methylation as a universal biomarker. Expert Rev Mol Diagn (2010) 1.18
Methylation of cell-free circulating DNA in the diagnosis of cancer. Front Mol Biosci (2015) 1.04
Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn (2015) 1.04
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol (2010) 1.03
"Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med (2015) 1.01
DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer (2011) 0.99
DNA methylation as clinically useful biomarkers-light at the end of the tunnel. Pharmaceuticals (Basel) (2012) 0.99
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer (2013) 0.93
Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer (2010) 0.89
Improved blood tests for cancer screening: general or specific? BMC Cancer (2011) 0.88
Quantification of 5-methylcytosine, 5-hydroxymethylcytosine and 5-carboxylcytosine from the blood of cancer patients by an enzyme-based immunoassay. Anal Chim Acta (2014) 0.88
Body mass and DNA promoter methylation in breast tumors in the Western New York Exposures and Breast Cancer Study. Am J Clin Nutr (2011) 0.85
The MethDet: a technology for biomarker development. Expert Rev Mol Diagn (2011) 0.82
A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer (2015) 0.82
Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World J Gastroenterol (2014) 0.81
Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol (2016) 0.80
Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J Cancer Res Clin Oncol (2014) 0.79
DNA hybridization detection with 100 zM sensitivity using piezoelectric plate sensors with an improved noise-reduction algorithm. Analyst (2014) 0.79
Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer. Clin Epigenetics (2015) 0.78
Gene-Specific Promoter Methylation Status in Hormone-Receptor-Positive Breast Cancer Associates with Postmenopausal Body Size and Recreational Physical Activity. Int J Cancer Clin Res (2015) 0.77
Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions. Radiology (2015) 0.76
Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma. Clin Epigenetics (2016) 0.76
A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: sensitivity and specificity for the diagnosis of myocardial infarction. Int J Mol Med (2014) 0.76
Modification of the association between recreational physical activity and survival after breast cancer by promoter methylation in breast cancer-related genes. Breast Cancer Res (2017) 0.75
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol (2013) 3.11
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol (2005) 2.04
Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol (2006) 1.99
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Total pancreatectomy and islet autotransplantation in chronic pancreatitis: recommendations from PancreasFest. Pancreatology (2013) 1.67
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J (2007) 1.62
Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest Endosc (2007) 1.62
Reassessment of deferrals for tattooing and piercing. Transfusion (2009) 1.61
Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci (2010) 1.59
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg (2007) 1.58
Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol (2006) 1.58
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion (2007) 1.47
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg (2005) 1.46
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol (2004) 1.45
Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology (2008) 1.45
Effect of platelet additive solution on bacterial dynamics and their influence on platelet quality in stored platelet concentrates. Transfusion (2010) 1.42
Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res (2004) 1.42
Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol (2011) 1.40
Multiplex identification of gram-positive bacteria and resistance determinants directly from positive blood culture broths: evaluation of an automated microarray-based nucleic acid test. PLoS Med (2013) 1.40
A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol (2008) 1.40
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations. Int J Radiat Oncol Biol Phys (2012) 1.20
Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer (2009) 1.19
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol (2003) 1.18
Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: a prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg (2003) 1.18
A dosimetric comparison of MammoSite high-dose-rate brachytherapy and Xoft Axxent electronic brachytherapy. Brachytherapy (2007) 1.16
Investigating population risk factors of pancreatic cancer by evaluation of optical markers in the duodenal mucosa. Dis Markers (2008) 1.16
A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys (2005) 1.14
Pancreatic cancer and the FAMMM syndrome. Fam Cancer (2007) 1.13
Enhanced retrieval of DNA from human fecal samples results in improved performance of colorectal cancer screening test. J Mol Diagn (2004) 1.11
Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion (2008) 1.11
Donor understanding and attitudes about current and potential deferral criteria for high-risk sexual behavior. Transfusion (2011) 1.11
Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer. Int J Radiat Oncol Biol Phys (2012) 1.10
Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol (2006) 1.07
Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012. Pancreatology (2013) 1.07
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys (2011) 1.07
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg (2012) 1.06
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2007) 1.05
The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys (2010) 1.05
Validation and implementation of a new hemoglobinometer for donor screening at Canadian Blood Services. Transfusion (2012) 1.03
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol (2010) 1.03
Unique finding of a 2009 H1N1 influenza virus-positive clinical sample suggests matrix gene sequence variation. J Clin Microbiol (2009) 1.03
Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol (2008) 1.02
Differential methylation profile of ovarian cancer in tissues and plasma. J Mol Diagn (2008) 1.02
Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer (2005) 1.00
Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol (2010) 1.00
DNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps. Int J Cancer (2011) 0.99
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum. Arch Surg (2007) 0.99
False biomarker discovery due to reactivity of a commercial ELISA for CUZD1 with cancer antigen CA125. Clin Chem (2013) 0.96
Oxaliplatin-related acute myelogenous leukemia. Oncologist (2006) 0.96
Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients. Int J Radiat Oncol Biol Phys (2010) 0.96
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial. Int J Radiat Oncol Biol Phys (2004) 0.96
Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics (2011) 0.95
Pooling-based genome-wide association study implicates gamma-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology (2010) 0.94
Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency. Transfusion (2010) 0.94
Epidemiology of hepatitis B in Canadian blood donors. Transfusion (2008) 0.94
CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn (2009) 0.94
Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant (2005) 0.94
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis (2003) 0.91
High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant (2005) 0.91
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol (2013) 0.91
A visual approach to providing prognostic information to parents of children with retinoblastoma. Psychooncology (2009) 0.91
Inherited pancreatic cancer syndromes. Cancer J (2012) 0.90
Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. Hum Pathol (2009) 0.90
Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion (2007) 0.90
Agreement among RTOG sarcoma radiation oncologists in contouring suspicious peritumoral edema for preoperative radiation therapy of soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys (2013) 0.89
Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One (2013) 0.89
Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys (2010) 0.89
Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches. J Oncol (2010) 0.89
Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leuk Res (2003) 0.88
Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer. Int J Cancer (2013) 0.88
Laminin, gamma 2 (LAMC2): a promising new putative pancreatic cancer biomarker identified by proteomic analysis of pancreatic adenocarcinoma tissues. Mol Cell Proteomics (2013) 0.87
Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol (2006) 0.87
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl (2004) 0.87
A third course of anti-thymocyte globulin in aplastic anaemia is only beneficial in previous responders. Br J Haematol (2005) 0.86
Specific glycoforms of MUC5AC and endorepellin accurately distinguish mucinous from nonmucinous pancreatic cysts. Mol Cell Proteomics (2013) 0.86
Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol (2005) 0.86
Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol (2006) 0.86
An analysis of the bias in red blood cell hemolysis measurement using several analytical approaches. Clin Chim Acta (2012) 0.86